Antiverse’s latest funding round is a clear read-through on where European biotech capital is still concentrating: platforms that can translate computational design into wet-lab validated drug candidates. The UK-based company has raised EUR 8.84 million (reported as $9.3 million Series A) to scale its AI-driven antibody discovery engine and accelerate programmes toward in vivo efficacy work.
The round was led by Soulmates Ventures, with participation from Innovation Investment Capital and DOMiNO Ventures, alongside existing backers including Development Bank of Wales (DBW), Kadmos Capital, and i&i Biotech Fund.
Why this round matters
Investor appetite for AI in drug discovery has become more selective, with increasing emphasis on proof that models can generate candidates that survive experimental validation. Antiverse sits in the cohort aiming to close the persistent gap between in silico discovery and clinically relevant molecules by pairing computational design with wet-lab capabilities.
The company’s focus on antibody discovery also aligns with the continued pull of biologics, particularly where targets are hard to reach with small molecules. Verified reporting around the round links Antiverse to the broader wave of European financing for AI-native platforms seeking to address “undruggable” biology.
Use of proceeds: platform scale and pipeline pull-through
Antiverse said the funding will be used to:
- Scale its AI-designed antibody discovery platform
- Expand collaborative programmes with pharma and foundation partners
- Advance its internal pipeline toward in vivo efficacy studies and later-stage preclinical development
That mix matters. Platform companies often struggle to balance services-style collaboration revenue with the longer-dated value of proprietary assets. Antiverse is signalling it intends to do both: deepen partnerships to validate the engine while moving internal programmes further down the development path.
Syndicate composition: specialist signal, not generalist momentum
The investor group points to a healthcare-specialist underwriting lens rather than broad-based tech enthusiasm. Participants include:
- Innovation Investment Capital, described as a CCR-backed fund focused on regional technology
- Development Bank of Wales, a repeat investor in life sciences
- i&i Biotech Fund, indicating biotech focus within the syndicate
This matters for execution. Platform biotechs typically need patient capital and domain expertise around experimental design, translational strategy, and partnership structuring. A specialist-leaning syndicate can help, but it also tends to demand clearer milestone delivery.
Commercial positioning: partnership traction as validation
Antiverse has also been building external validation through partnerships. Recent examples cited in reporting include a research agreement with the Cystic Fibrosis Foundation and a prior deal with Japan’s Nxera Pharma. For AI-driven discovery companies, these relationships do double duty: they generate near-term funding and, more importantly, provide real-world feedback loops that can harden the platform’s predictive edge.
The round was announced in early 2026, in a period where EU policy and funding initiatives have continued to support AI applications in drug discovery. The strategic question is whether that supportive backdrop translates into faster preclinical progression for companies that can consistently convert model outputs into robust biological results.
Key questions for the next phase
With terms undisclosed beyond the headline amount, the market will focus less on valuation and more on execution proof points:
- Translation rate: How reliably can Antiverse turn computational hits into antibodies that show potency, developability, and clean off-target profiles in the lab?
- Partner economics: Are collaborations structured as research fees only, or do they include downstream milestones and royalties that meaningfully de-risk the model?
- Pipeline prioritisation: Which internal programmes will be pushed toward in vivo efficacy first, and what constitutes success at that stage?
- Operational scaling: Does the company have the wet-lab throughput, automation, and assay depth to keep model iteration cycles tight as it grows?
What to watch next
- Timing and scope of in vivo efficacy readouts from lead internal programmes
- Additional pharma partnerships, and whether they include downstream economics
- Evidence of improved hit-to-lead and lead-optimisation cycles as the platform scales
- Hiring and capex signals that indicate wet-lab capacity expansion and execution bandwidth
- Any disclosed path toward IND-enabling work and preclinical package requirements